Mitsubishi Tanabe Pharma Corporation

Yoshitomi Pharmaceutical Industries, Ltd.

Mitsubishi Pharma Corporation

Seigo Ishibuchi

Yoichi Naka

Katsuhiko Itoh

Hidemasa Hikawa

Jun-ichi Endoh

Akiko Tarao

Hiroshi Sumichika

Kazuhiro Maeda

Kunitomo Adachi

Maiko Hamada

Kaoru Tashiro

Naoto Fujie

Mitsuharu Nakamura

Takao Kamahori

Jun-Ichi Endoh

Minoru Tanaka

Naoki Sugiyama

Kenji Chiba

Kunio Sugahara

Kenji Morokuma

Kunio Saruta

Tetsuji Matsudaira

Takanobu Kuroita

Hiroshi Tanaka

Takafumi Kawaguchi

Makio Ohtsuki

Hiroshi Morimoto

Hiroyuki Ushio

Maki Seki

Youichiro Naito

Yoshifumi Togo

Takashi Futamura

Masakazu Fujio

Takashi Honjo

Hiroyoshi Inoue

Atsushi Fukunari

Nobuatsu Matoba

Shingo Ogata

Atsushi Kawata

Kouichi Oshita

Yukio Aoyama

Meguru Murata

Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.

Imide derivatives and use thereof as medicine

Provided are a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2, as well as a prophylactic/therapeutic drug for autoimmune diseases or osteoarthritis. An amide derivative represented by the following formula (I) wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof.

Amide derivative and use thereof as medicine

Provided are a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2, as well as a prophylactic/therapeutic drug for autoimmune diseases or osteoarthritis. An amide derivative represented by the following formula (I) wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof.

Oxazolidinone amide aromatic compounds for supressing MMP-9 production

The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic action wherein each symbol is as defined in the specification. The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis and pancreatitis and the like) due to activation of leukocytes caused by ischemia reperfusion, trauma, burn, surgical invasion and the like]. Moreover, they are useful as a therapeutic or prophylactic agent for the infectious diseases caused by bacteria and virus that invade via a C5a receptor.

Amide derivatives and medicinal use thereof

A thienotriazolodiazepine compound of the following formula (I) a pharmaceutical agent containing the compound as an active ingredient, and a production intermediate and a production method of the thienotriazolodiazepine compound. Since this compound has an inhibitory action on costimulatory signal from CD28 on T cell, it is useful for the prophylaxis or suppression of rejection reaction in transplantation of organ or bone marrow and the like, and the prophylaxis or treatment of autoimmune diseases or allergic diseases.

Thienotriazolodiazepine compound and medicinal use thereof

The present invention relates to a urea derivative of the formula (1) wherein each symbol is as described in the specification, a pharmaceutically acceptable salt thereof and pharmaceutical use thereof. The compound of the present invention has a C5a receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of diseases or syndromes due to inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis, pancreatitis and the like) due to activation of leukocytes caused by ischemia, trauma, burn, surgical invasion and the like]. In addition, it is useful as an agent for the prophylaxis or treatment of infectious diseases caused by bacteria or virus that invades via a C5a receptor.

3-substituted urea derivatives and medicinal use thereof

The present invention relates to a compound of the formulawherein Ris substituted aryl, heteroaryl and the like, Rand Rare hydrogen, alkyl, halogen, hydroxyl group and the like, Q is N, CH and the like, W is hydrogen, alkyl, hydroxycarbonylalkyl and the like, X is halogen, cyano, nitro, amino and the like, X' is hydrogen, halogen, cyano, nitro, and Y is alkyl, hydroxyl group, alkoxy, mercapto and the like and a salt thereof, and a medicine containing the said compound. The compound of the present invention shows a superior inhibitory effect on activated lymphocytes proliferation and is useful as an agent for the prophylaxis or treatment of various autoimmune diseases.

Amide compounds and medicinal use thereof

The present invention relates to a fused heterocyclic compound of the formula (I)

Fused heterocyclic compounds and pharmaceutical applications thereof

1-phenylpyrazole compounds and medicinal application thereof

Growing community of inventors

Osaka, Japan

Seigo Ishibuchi